Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Salix Pharmaceuticals discusses proposed rifaximin NDA with the FDA

Salix Pharmaceuticals, Ltd. today reported that the Company held a pre-NDA meeting on December 8, 2009 with the FDA to discuss the Company’s proposed new drug application (NDA) for rifaximin in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS).

10 Dec 2009

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from the Tulip PETAL Study (703 Study), its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

10 Dec 2009

Decision Resources reports increased uptake of TNF-alpha inhibitors for Crohn's disease

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that compared to last year's analysis of U.S. patient-level claims data, TNF-alpha inhibitors are being used more often to treat newly diagnosed patients suffering from Crohn's disease.

9 Dec 2009

Research article addresses the relationship between PEG and GER

Gastroesophageal reflux (GER) is a common problem in mechanically ventilated patients and contributes to the development of esophageal mucosal injury and even erosive esophagitis. The relationship between percutaneous endoscopic gastrostomy (PEG) and subsequent development of GER is complex and not well understood.

9 Dec 2009

Research article on Peliosis hepatis

Peliosis hepatis (PH) is a rare pathological entity. PH varies from minimal asymptomatic lesions to larger massive lesions that may present with cholestasis, liver failure, portal hypertension, avascular mass lesion, or even spontaneous rupture.

9 Dec 2009

Comparative study on erosive and nonerosive diseases

Gastroesophageal reflux disease (GERD) is defined as the pathological retrograde movement of gastric contents into the esophagus. Various esophageal motility disturbances which may be important in reflux are observed in patients with GERD.

9 Dec 2009

Utility of CEH-EUS uses sonographic contrast agent to diagnose pancreatic tumors

Endoscopic ultrasonography (EUS) is a highly sensitive diagnostic method for the detection of small pancreatic carcinomas. Recently, there have been some reports describing the utility of contrast-enhanced harmonic EUS (CEH-EUS) which uses sonographic contrast agent for differentiation of a pancreatic mass.

9 Dec 2009

HALO procedure can help manage Barrett's esophagus and prevent esophageal cancer

Cancer prevention is an important goal for all Houstonians and Bay Area Gastroenterology advises that early detection can prevent esophageal cancer.

8 Dec 2009

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in its Phase I/IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in combination with standard antiviral treatment and vaccination in HBeAg-negative chronic hepatitis B-infected (HBV) patients.

8 Dec 2009

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

In addition to data released in late November, ChemoCentryx, Inc., announced today more data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease.

8 Dec 2009

Norovirus-related illnesses linked to eating oysters, reveals report

The U.S. Food and Drug Administration is advising consumers to avoid eating oysters harvested from the San Antonio Bay on or after Nov. 16 due to reports of norovirus-associated illnesses in some people who had consumed oysters harvested from this area, which is located on the Gulf of Texas.

7 Dec 2009

Lab grown muscle cells raise hope for gastric reflux and fecal incontinence

A new study shows that muscle cells grown in the lab can restore an intestine's ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat patients with conditions such as gastric reflux and fecal incontinence.

5 Dec 2009

FDA approves Santarus’ NDA for immediate-release prescription tablet product

Santarus, Inc., a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s New Drug Application (NDA) for immediate-release omeprazole/sodium bicarbonate/ magnesium hydroxide tablets in 40 mg and 20 mg dosage strengths of omeprazole.

5 Dec 2009

PLUS Diagnostics expands its specialty anatomic pathology services

PLUS Diagnostics announced today that it has expanded its specialty anatomic pathology services with the launch of a national hematology/oncology offering. The new service completes the company's expansion from a regional laboratory to a leading national anatomic pathology company offering diagnostic services across a full range of specialties including gastroenterology, urology and now hematology/oncology.

4 Dec 2009

Results from Phase III pivotal study of FIRMAGON presented

Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurrence rate in a Phase III pivotal study of FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in prostate cancer patients during the first year of treatment.

4 Dec 2009

New Center for Digestive Care to care for all aspects of digestive disease

The Center for Digestive Care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center has been established with a mission to provide high-quality patient care, research and education for all aspects of digestive disease.

4 Dec 2009

Data from recent clinical trial for Caldolor Injection to be presented

Cumberland Pharmaceuticals Inc. announced today that data from a recent clinical trial for Caldolor® (ibuprofen) Injection, an intravenous treatment for pain and fever, will be presented at the 44th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting in Las Vegas, Nevada, in December.

4 Dec 2009

FDA approves manufacture of Amneal Pharmaceuticals' Nizatidine Oral Solution

Amneal Pharmaceuticals is pleased to announce that it has received U.S. FDA approval to manufacture Nizatidine Oral Solution in the 15 mg/mL strength effective November 18, 2009. It is an AA-rated, therapeutically equivalent alternative to Axid® Oral Solution (a licensed trademark of Braintree Labs). Nizatidine Oral Solution is the first available generic in oral solution form and marks Amneal’s fourth liquid approval.

3 Dec 2009

Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

Hyperion Therapeutics, Inc. today announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate).

3 Dec 2009

Nonanesthesiologist-administered propofol for GI procedures safe

The worldwide safety experience of endoscopist-administered propofol sedation now exceeds 600,000 patients. The low rate of serious adverse events underscores the safety of nonanesthesiologist-administered propofol (NAAP) for gastrointestinal (GI) procedures, provided that it is administered by a team of individuals who have received training specific to the administration of propofol according to the "Position statement: nonanesthesiologist administration of propofol for GI endoscopy" issued by the four major gastroenterology and hepatology societies.

3 Dec 2009

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Salix Pharmaceuticals discusses proposed rifaximin NDA with the FDA

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Decision Resources reports increased uptake of TNF-alpha inhibitors for Crohn's disease

Research article addresses the relationship between PEG and GER

Research article on Peliosis hepatis

Comparative study on erosive and nonerosive diseases

Utility of CEH-EUS uses sonographic contrast agent to diagnose pancreatic tumors

HALO procedure can help manage Barrett's esophagus and prevent esophageal cancer

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

Norovirus-related illnesses linked to eating oysters, reveals report

Lab grown muscle cells raise hope for gastric reflux and fecal incontinence

FDA approves Santarus’ NDA for immediate-release prescription tablet product

PLUS Diagnostics expands its specialty anatomic pathology services

Results from Phase III pivotal study of FIRMAGON presented

New Center for Digestive Care to care for all aspects of digestive disease

Data from recent clinical trial for Caldolor Injection to be presented

FDA approves manufacture of Amneal Pharmaceuticals' Nizatidine Oral Solution

Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

Nonanesthesiologist-administered propofol for GI procedures safe

Your full guide to the gut microbiome eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Your full guide to the gut microbiome eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in